210 related articles for article (PubMed ID: 15515406)
21. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
Navari RM
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251
[TBL] [Abstract][Full Text] [Related]
22. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
23. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer.
Pinarli FG; Elli M; Dagdemir A; Baysal K; Acar S
Pediatr Blood Cancer; 2006 Oct; 47(5):567-71. PubMed ID: 16317736
[TBL] [Abstract][Full Text] [Related]
24. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative nausea and vomiting after craniotomy: a meta-analysis.
Neufeld SM; Newburn-Cook CV
J Neurosurg Anesthesiol; 2007 Jan; 19(1):10-7. PubMed ID: 17198095
[TBL] [Abstract][Full Text] [Related]
26. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
[TBL] [Abstract][Full Text] [Related]
27. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
Sorbe BG; Berglind AM; Andersson H; Boman K; Högberg T; Hallgren M; Schmidt M
Cancer; 1998 Sep; 83(5):1022-32. PubMed ID: 9731907
[TBL] [Abstract][Full Text] [Related]
28. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
Gridelli C
Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
[TBL] [Abstract][Full Text] [Related]
29. Granisetron: is there a dose-response effect on nausea and vomiting?
Minami M
Cancer Chemother Pharmacol; 2003 Aug; 52(2):89-98. PubMed ID: 12783208
[TBL] [Abstract][Full Text] [Related]
30. Physiology and pathophysiology of the 5-HT3 receptor.
Färber L; Haus U; Späth M; Drechsler S
Scand J Rheumatol Suppl; 2004; 119():2-8. PubMed ID: 15515404
[TBL] [Abstract][Full Text] [Related]
31. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
[TBL] [Abstract][Full Text] [Related]
32. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis.
Rojas C; Raje M; Tsukamoto T; Slusher BS
Eur J Pharmacol; 2014 Jan; 722():26-37. PubMed ID: 24184669
[TBL] [Abstract][Full Text] [Related]
33. The development of a protocol for the use of 5-HT3 antagonists in chemotherapy-induced nausea and vomiting.
Watters J; Riley M; Pedley I; Whitehead A; Overend M; Goss I; Allgar V
Clin Oncol (R Coll Radiol); 2001; 13(6):422-6. PubMed ID: 11824878
[TBL] [Abstract][Full Text] [Related]
34. Analgesic effects of 5-HT3 receptor antagonists.
Riering K; Rewerts C; Zieglgänsberger W
Scand J Rheumatol Suppl; 2004; 119():19-23. PubMed ID: 15515407
[TBL] [Abstract][Full Text] [Related]
35. Advances in use of the 5-HT3 receptor antagonists.
Walton SM
Expert Opin Pharmacother; 2000 Jan; 1(2):207-23. PubMed ID: 11249543
[TBL] [Abstract][Full Text] [Related]
36. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting.
Rabasseda X
Drugs Today (Barc); 2002 Feb; 38(2):75-89. PubMed ID: 12532186
[TBL] [Abstract][Full Text] [Related]
37. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?
Gan TJ
CNS Drugs; 2005; 19(3):225-38. PubMed ID: 15740177
[TBL] [Abstract][Full Text] [Related]
38. [Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].
Alon E; Biro P
Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 May; 31(4):200-4. PubMed ID: 8704077
[TBL] [Abstract][Full Text] [Related]
39. Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting.
Kovac AL
Drug Saf; 2003; 26(4):227-59. PubMed ID: 12608887
[TBL] [Abstract][Full Text] [Related]
40. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists.
Wolf H
Scand J Rheumatol Suppl; 2000; 113():37-45. PubMed ID: 11028830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
